Trial Profile
Motion Syros: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Travel
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary)
- Indications Motion sickness
- Focus Registrational; Therapeutic Use
- Acronyms Motion Syros
- Sponsors Vanda Pharmaceuticals
- 19 Mar 2024 Status changed from active, no longer recruiting to completed.
- 25 May 2023 Results presented in Vanda Pharmaceuticals media release.
- 25 May 2023 Primary endpoint (Reduction in the incidence of vomiting as measured by the MSSS) has been met, according to a Vanda Pharmaceuticals media release.